2023
Quantifying the impact of immunotherapy on RNA dynamics in cancer
Usaite I, Biswas D, Dijkstra K, Watkins T, Pich O, Puttick C, Angelova M, Thakkar K, Hiley C, Birkbak N, Kok M, Zaccaria S, Wu Y, Litchfield K, Swanton C, Kanu N. Quantifying the impact of immunotherapy on RNA dynamics in cancer. Journal For ImmunoTherapy Of Cancer 2023, 11: e007870. PMID: 37914385, PMCID: PMC10626770, DOI: 10.1136/jitc-2023-007870.Peer-Reviewed Original ResearchConceptsCheckpoint inhibitorsCheckpoint inhibitor treatmentBreast cancerOn-therapyImmune microenvironmentPre-therapyCancer typesPatients treated with checkpoint inhibitorsCheckpoint inhibitor therapyImpact of immunotherapyCancer immune microenvironmentSolid tumor typesMechanism of sensitizationClinical responseCombination therapyTumor typesIO targetsResponse ratePatientsBreastCancerImmunotherapyMelanomaMeta-analysesTherapy
2019
An innate-like Vδ1+ γδ T cell compartment in the human breast is associated with remission in triple-negative breast cancer
Wu Y, Kyle-Cezar F, Woolf R, Naceur-Lombardelli C, Owen J, Biswas D, Lorenc A, Vantourout P, Gazinska P, Grigoriadis A, Tutt A, Hayday A. An innate-like Vδ1+ γδ T cell compartment in the human breast is associated with remission in triple-negative breast cancer. Science Translational Medicine 2019, 11 PMID: 31597756, PMCID: PMC6877350, DOI: 10.1126/scitranslmed.aax9364.Peer-Reviewed Original ResearchConceptsT cell compartmentT cell receptorTriple-negative breast cancerInnate-like responsesT cellsBreast cancerExpress T cell receptorsIFN-g productionProgression-free survivalHuman breastAntigen-specific responsesAssociated with remissionHuman breast tumorsT cell receptor signalingMaximal patient benefitProgression-freeNKG2D receptorOverall survivalPeripheral bloodTissue-residentBreast tumorsIFN-gIL-17Paired tumorInflammatory pathology